Humanigen claims a Covid-19 win with lenzilumab
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
Astra’s Covid-19 vaccine: much ado about nothing?
With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.
Better late than never for Boehringer in Covid-19
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Obfuscation and evasion: Astra shows how not to disclose data
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
Astrazeneca silences its Covid-19 vaccine doubters
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
Roche buys Genmark for Covid-19 tests and more
At $1.8bn the acquisition is Roche’s biggest diagnostics deal since it bought Foundation Medicine in 2018.
Humanigen claims a Covid-19 win with lenzilumab
But the company focused on a modified intent-to-treat analysis of its pivotal trial.
Astra’s Covid-19 vaccine: much ado about nothing?
With results of the full primary analysis now out the spotlight falls on a further 14 as yet unadjudicated Covid-19 cases.
Better late than never for Boehringer in Covid-19
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Obfuscation and evasion: Astra shows how not to disclose data
The UK group’s disastrous PR strategy could erode trust in its Covid-19 vaccine even further.
Astrazeneca silences its Covid-19 vaccine doubters
AZD1222 could be rehabilitated by US pivotal trial data showing efficacy of 79%, with no worries about blood clots.
Roche buys Genmark for Covid-19 tests and more
At $1.8bn the acquisition is Roche’s biggest diagnostics deal since it bought Foundation Medicine in 2018.
